Down regulation of miR-202 modulates Mxd1 and Sin3A repressor complexes to induce apoptosis of pancreatic cancer cells

Cancer Biology and Therapy

Volumn 16, Issue 1, 2015, Pages 115-124

  Farhana, Lulu ^a,b,c   Dawson, Marcia I ^d   Fontana, Joseph A ^a,b,c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

^c KARMANOS CANCER INSTITUTE   (United States)

^d BURNHAM INSTITUTE   (United States)

Author keywords

c Myc; hTERT; miR 202; miR 578; Mxd1 Mad1; pancreatic cancer; SAP18; Sin3A

Indexed keywords

HISTONE DEACETYLASE 2; MAX DIMERIZATION PROTEIN 1; MESSENGER RNA; MICRORNA; MICRORNA 202; MICRORNA 578; MYC PROTEIN; PROTEIN; SIN3A ASSOCIATED PROTEIN 18; SYNAPSIN I; TELOMERASE REVERSE TRANSCRIPTASE; TRANSCRIPTION FACTOR SIN3A; UNCLASSIFIED DRUG; 3' UNTRANSLATED REGION; 4-(3-(1-ADAMANTYL)-4-HYDROXYPHENYL)-3-CHLOROCINNAMIC ACID; ADAMANTANE; BASIC HELIX LOOP HELIX LEUCINE ZIPPER TRANSCRIPTION FACTOR; CINNAMIC ACID DERIVATIVE; MIRN202 MICRORNA, HUMAN; MXD1 PROTEIN, HUMAN; PROTEIN BINDING; REPRESSOR PROTEIN; SIN3A TRANSCRIPTION FACTOR; TELOMERASE; TERT PROTEIN, HUMAN;

3' UNTRANSLATED REGION; APOPTOSIS; ARTICLE; CELL TRANSFORMATION; CONTROLLED STUDY; DNA FRAGMENTATION; ENZYME ACTIVITY; GENE REPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; PANCREAS CANCER; PANCREATIC CANCER CELL LINE; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR DOWN REGULATION; ANALOGS AND DERIVATIVES; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PANCREAS TUMOR; RNA INTERFERENCE; TUMOR CELL LINE;

3' UNTRANSLATED REGIONS; ADAMANTANE; APOPTOSIS; BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; CELL LINE, TUMOR; CINNAMATES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; PANCREATIC NEOPLASMS; PROTEIN BINDING; REPRESSOR PROTEINS; RNA INTERFERENCE; TELOMERASE;

EID: 84946721321     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/15384047.2014.987070     Document Type: Article

References (46)

1. Lee YS, Dutta A. MicroRNAs in cancer. Annu Rev Pathol 2009; 4:199-227; PMID:18817506; http://dx.doi.org/10.1146/annurev.pathol.4.110807.092222
2. Srinivasan S, Selvan ST, Archunan G, Gulyas B, Padmanabhan P. MicroRNAs -the next generation therapeutic targets in human diseases. Theranostics 2013; 3:930-42; PMID:24396504; http://dx.doi.org/10.7150/thno.7026
3. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A 2004; 101:2999-3004; PMID:14973191; http://dx.doi.org/10.1073/pnas.0307323101
4. Kumar MS, Lu J, Mercer KL, Golub TR, Jacks T. Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet 2007; 39:673-7; PMID:17401365; http://dx.doi.org/10.1038/ng2003
5. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 2006; 103:2257-61; PMID:16461460; http://dx.doi.org/10.1073/pnas.0510565103
6. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005; 65:7065-70; PMID:16103053; http://dx.doi.org/10.1158/0008-5472.CAN-05-1783
7. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, et al. MicroRNA expression profiles classify human cancers. Nature 2005; 435:834-8; PMID:15944708; http://dx.doi.org/10.1038/nature03702
8. Zhang Y, Dai Y, Huang Y, Ma L, Yin Y, Tang M, Hu C. Microarray profile of micro-ribonucleic acid in tumor tissue from cervical squamous cell carcinoma without human papillomavirus. J Obstet Gynaecol Res 2009; 35: 842-9; PMID:20149030; http://dx.doi.org/10.1111/j.1447-0756.2009.01055.x
9. Ng EK, Chong WW, Jin H, Lam EK, Shin VY, Yu J, Poon TC, Ng SS, Sung JJ. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut 2009; 58:1375-81; PMID:19201770; http://dx.doi.org/10.1136/gut.2008.167817
10. Jiang Z, Guo J, Xiao B, Miao Y, Huang R, Li D, Zhang Y. Increased expression of miR-421 in human gastric carcinoma and its clinical association. J Gastroenterol 2010; 45:17-23; PMID:19802518; http://dx.doi.org/10.1007/s00535-009-0135-6
11. Zhao Y, Li C, Wang M, Su L, Qu Y, Li J, Yu B, Yan M, Yu Y, Liu B, et al. Decrease of miR-202-3p expression, a novel tumor suppressor, in gastric cancer. PLoS One 2013; 8:e69756; PMID:23936094; http://dx.doi.org/10.1371/journal.pone.0069756
12. Wang W, Corrigan-Cummins M, Hudson J, Maric I, Simakova O, Neelapu SS, Kwak LW, Janik JE, Gause B, Jaffe ES, et al. MicroRNA profiling of follicular lymphoma identifies microRNAs related to cell proliferation and tumor response. Haematologica 2012; 97:586-94; PMID:22102710; http://dx.doi.org/10.3324/haematol.2011.048132
13. Hoffman AE, Zheng T, Yi C, Leaderer D, Weidhaas J, Slack F, Zhang Y, Paranjape T, Zhu Y. microRNA miR-196a-2 and breast cancer: a genetic and epigenetic association study and functional analysis. Cancer Res 2009; 69: 5970-7; PMID:19567675; http://dx.doi.org/10.1158/0008-5472.CAN-09-0236
14. Yu J, Qiu X, Shen X, Shi W, Wu X, Gu G, Zhu B, Ju S. miR-202 expression concentration and its clinical significance in the serum of multiple myeloma patients. Ann Clin Biochem 2013; http://dx.doi.org/10.1177/0004563213501155; Epub 2013 Sep
15. Park JY, Helm J, Coppola D, Kim D, Malafa M, Kim SJ. MicroRNAs in pancreatic ductal adenocarcinoma. World J Gastroenterol 2011; 17: 817-27; PMID:21412491; http://dx.doi.org/10.3748/wjg.v17.i7.817
16. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009; 136: 215-33; PMID:19167326; http://dx.doi.org/10.1016/j.cell.2009.01.002
17. Costa PM, Pedroso de Lima MC. MicroRNAs as Molecular Targets for Cancer Therapy: On the Modulation of MicroRNA Expression. Pharmaceuticals (Basel) 2013; 6:1195-220; PMID:24275848; http://dx.doi.org/10.3390/ph6101195
18. Dawson MI, Fontana JA. The peptidomimetic, 1-adamantyl-substituted, and flex-het classes of retinoid-derived molecules: structure-activity relationships and retinoid receptor-independent anticancer activities. Mini Rev Med Chem 2010; 10:455-91; PMID:20370709; http://dx.doi.org/10.2174/138955710791384045
19. Farhana L, Dawson MI, Das JK, Murshed F, Xia Z, Hadden TJ, Hatfield J, Fontana JA. Adamantyl Retinoid-Related Molecules Induce Apoptosis in Pancreatic Cancer Cells by Inhibiting IGF-1R and Wnt/beta-Catenin Pathways. J Oncol 2012; 2012:796729; PMID:22570653; http://dx.doi.org/10.1155/2012/796729
20. Farhana L, Dawson MI, Murshed F, Das JK, Rishi AK, Fontana JA. Upregulation of miR-150* and miR-630 induces apoptosis in pancreatic cancer cells by targeting IGF-1R. PLoS One 2013; 8:e61015; PMID:23675407; http://dx.doi.org/10.1371/journal.pone.0061015
21. Ayer DE, Lawrence QA, Eisenman RN. Mad-Max transcriptional repression is mediated by ternary complex formation with mammalian homologs of yeast repressor Sin3. Cell 1995; 80:767-76; PMID:7889570; http://dx.doi.org/10.1016/0092-8674(95)90355-0
22. Ayer DE, Laherty CD, Lawrence QA, Armstrong AP, Eisenman RN. Mad proteins contain a dominant transcription repression domain. Mol Cell Biol 1996; 16:5772-81; PMID:8816491
23. Schreiber-Agus N, Chin L, Chen K, Torres R, Rao G, Guida P, Skoultchi AI, DePinho RA. An amino-terminal domain of Mxi1 mediates anti-Myc oncogenic activity and interacts with a homolog of the yeast transcriptional repressor SIN3. Cell 1995; 80:777-86; PMID:7889571; http://dx.doi.org/10.1016/0092-8674(95)90356-9
24. Gehring S, Rottmann S, Menkel AR, Mertsching J, Krippner-Heidenreich A, Luscher B. Inhibition of proliferation and apoptosis by the transcriptional repressor Mad1. Repression of Fas-induced caspase-8 activation. J Biol Chem 2000; 275:10413-20; PMID:10744730; http://dx.doi.org/10.1074/jbc.275.14.10413
25. Hurlin PJ, Foley KP, Ayer DE, Eisenman RN, Hanahan D, Arbeit JM. Regulation of Myc and Mad during epidermal differentiation and HPV-associated tumorigenesis. Oncogene 1995; 11:2487-501; PMID:8545105
26. Grandori C, Cowley SM, James LP, Eisenman RN. The Myc/Max/Mad network and the transcriptional control of cell behavior. Annu Rev Cell Dev Biol 2000; 16:653-99; PMID:11031250; http://dx.doi.org/10.1146/annurev.cellbio.16.1.653
27. Luscher B. MAD1 and its life as a MYC antagonist: an update. Eur J Cell Biol 2012; 91:506-14; PMID:21917351; http://dx.doi.org/10.1016/j.ejcb.2011.07.005
28. Cascon A, Robledo M. MAX and MYC: a heritable breakup. Cancer Res 2012; 72:3119-24; PMID:22706201; http://dx.doi.org/10.1158/0008-5472.CAN-11-3891
29. Xu D, Popov N, Hou M, Wang Q, Bjorkholm M, Gruber A, Menkel AR, Henriksson M. Switch from Myc/Max to Mad1/Max binding and decrease in histone acetylation at the telomerase reverse transcriptase promoter during differentiation of HL60 cells. Proc Natl Acad Sci U S A 2001; 98:3826-31; PMID:11274400; http://dx.doi.org/10.1073/pnas.071043198
30. Zhang Y, Dawson MI, Ning Y, Polin L, Parchment RE, Corbett T, Mohamed AN, Feng KC, Farhana L, Rishi AK, et al. Induction of apoptosis in retinoid-refractory acute myelogenous leukemia by a novel AHPN analog. Blood 2003; 102:3743-52; PMID:12893763; http://dx.doi.org/10.1182/blood-2003-01-0108
31. Dawson MI, Harris DL, Liu G, Hobbs PD, Lange CW, Jong L, Bruey-Sedano N, James SY, Zhang XK, Peterson VJ, et al. Antagonist analogue of 6-[3′-(1-adamantyl)-4′-hydroxyphenyl]-2-naphthalenecarboxylic acid (AHPN) family of apoptosis inducers that effectively blocks AHPN-induced apoptosis but not cell-cycle arrest. J Med Chem 2004; 47:3518-36; PMID:15214780; http://dx.doi.org/10.1021/jm030524k
32. Zhang Y, Zheng D, Xiong Y, Xue C, Chen G, Yan B, Ye Q. miR-202 suppresses cell proliferation in human hepatocellular carcinoma by downregulating LRP6 post-transcriptionally. FEBS Lett 2014; 588:1913-20; PMID:24704686; http://dx.doi.org/10.1016/j.febslet.2014.03.030
33. Bisio A, De Sanctis V, Del Vescovo V, Denti MA, Jegga AG, Inga A, Ciribilli Y. Identification of new p53 target microRNAs by bioinformatics and functional analysis. BMC Cancer 2013; 13:552; PMID:24256616; http://dx.doi.org/10.1186/1471-2407-13-552
34. Wu Q, Yang Z, An Y, Hu H, Yin J, Zhang P, Nie Y, Wu K, Shi Y, Fan D. MiR-19a/b modulate the metastasis of gastric cancer cells by targeting the tumour suppressor MXD1. Cell Death Dis 2014; 5:e1144; PMID:24675462; http://dx.doi.org/10.1038/cddis.2014.110
35. Salehi-Tabar R, Nguyen-Yamamoto L, Tavera-Mendoza LE, Quail T, Dimitrov V, An BS, Glass L, Goltzman D, White JH. Vitamin D receptor as a master regulator of the c-MYC/MXD1 network. Proc Natl Acad Sci U S A 2012; 109:18827-32; PMID:23112173; http://dx.doi.org/10.1073/pnas.1210037109
36. Dang CV. MYC on the path to cancer. Cell 2012; 149:22-35; PMID:22464321; http://dx.doi.org/10.1016/j.cell.2012.03.003
37. Dalla-Favera R, Bregni M, Erikson J, Patterson D, Gallo RC, Croce CM. Human c-myc oncogene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Natl Acad Sci U S A 1982; 79:7824-7; PMID:6961453; http://dx.doi.org/10.1073/pnas.79.24.7824
38. Shou Y, Martelli ML, Gabrea A, Qi Y, Brents LA, Roschke A, Dewald G, Kirsch IR, Bergsagel PL, Kuehl WM. Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma. Proc Natl Acad Sci U S A 2000; 97:228-33; PMID:10618400; http://dx.doi.org/10.1073/pnas.97.1.228
39. Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, Barretina J, Boehm JS, Dobson J, Urashima M, et al. The landscape of somatic copy-number alteration across human cancers. Nature 2010; 463:899-905; PMID:20164920; http://dx.doi.org/10.1038/nature08822
40. Akagi K, Suzuki T, Stephens RM, Jenkins NA, Copeland NG. RTCGD: retroviral tagged cancer gene database. Nucleic Acids Res 2004; 32:D523-7; PMID:14681473; http://dx.doi.org/10.1093/nar/gkh013
41. Beer S, Zetterberg A, Ihrie RA, McTaggart RA, Yang Q, Bradon N, Arvanitis C, Attardi LD, Feng S, Ruebner B, et al. Developmental context determines latency of MYC-induced tumorigenesis. PLoS Biol 2004; 2:e332; PMID:15455033
42. Arvanitis C, Felsher DW. Conditional transgenic models define how MYC initiates and maintains tumorigenesis. Semin Cancer Biol 2006; 16:313-7; PMID:16935001; http://dx.doi.org/10.1016/j.semcancer.2006.07.012
43. Amati B, Brooks MW, Levy N, Littlewood TD, Evan GI, Land H. Oncogenic activity of the c-Myc protein requires dimerization with Max. Cell 1993; 72:233-45; PMID:8425220; http://dx.doi.org/10.1016/0092-8674(93)90663-B
44. Grzenda A, Lomberk G, Zhang JS, Urrutia R. Sin3: master scaffold and transcriptional corepressor. Biochim Biophys Acta 2009; 1789:443-50; PMID:19505602; http://dx.doi.org/10.1016/j.bbagrm.2009.05.007
45. Fontana JA, Dawson MI, Leid M, Rishi AK, Zhang Y, Hsu CA, Lu JS, Peterson VJ, Jong L, Hobbs P, et al. Identification of a unique binding protein specific for a novel retinoid inducing cellular apoptosis. Int J Cancer 2000; 86:474-9; PMID:10797258; http://dx.doi.org/10.1002/(SICI)1097-0215(20000515)86:4%3c474::AID-IJC5%3e3.0.CO;2-Z
46. Farhana L, Dawson MI, Fontana JA. Apoptosis induction by a novel retinoid-related molecule requires nuclear factor-kappaB activation. Cancer Res 2005; 65:4909-17; PMID:15930313; http://dx.doi.org/10.1158/0008-5472.CAN-04-4124